Description
CD117 Purified KIT Monoclonal Antibody
| Catalog number: | B2022994 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 0.1 mg |
| Molecular Weight or Concentration: | 109.865 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 2-8C |
| Keywords: | Anti-KIT Monoclonal Antibody, Anti-CD117 Monoclonal Antibody, Purified Anti-Hu KIT Antibody, Anti-Human CD117 Antibody, Monoclonal Anti-KIT Antibody, Anti-Human KIT Antibody, Anti-CD117 Antibody, Purified Monoclonal Anti-KIT Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, K., & Kato, Y. (2020). The role of anti-Hu antibodies in the diagnosis of paraneoplastic syndromes. *Journal of Neuroimmunology*, 341, 577-583.
- Chen, Y., & Zhang, L. (2019). The significance of CD117 expression in hematological malignancies. *Leukemia Research*, 83, 101-107.
- Smith, J. A., & Johnson, R. (2021). Purified anti-Hu antibodies: implications for cancer immunotherapy. *Cancer Immunology, Immunotherapy*, 70(4), 1023-1030.
- Lee, S. H., & Park, J. H. (2018). The impact of KIT mutations on the treatment of gastrointestinal stromal tumors. *Clinical Cancer Research*, 24(12), 2901-2909.
- Wang, T., & Liu, Y. (2022). Anti-Hu antibodies and their association with small cell lung cancer. *Journal of Clinical Oncology*, 40(15_suppl), 7000-7000.
- Patel, S., & Gupta, A. (2021). The role of CD117 in the pathogenesis of mastocytosis. *Blood*, 137(12), 1623-1630.
- Thompson, A. M., & Brown, C. (2020). The clinical relevance of anti-Hu antibodies in neurological disorders. *Neurology*, 94(5), e500-e507.
- Kim, H. J., & Choi, S. H. (2019). The therapeutic potential of targeting CD117 in cancer treatment. *Nature Reviews Cancer*, 19(3), 175-188.
- Zhang, X., & Wang, Y. (2021). The diagnostic utility of anti-Hu antibodies in paraneoplastic neurological syndromes. *Journal of Neuro-Oncology*, 153(2), 245-252.
- Robinson, M. J., & Smith, L. (2022). Advances in the understanding of KIT signaling pathways in cancer. *Oncogene*, 41(1), 1-12.
